Molecular markers for detection, surveillance and prognostication of bladder cancer (Q37418122)

20 August 2017

1 reference

title

Molecular markers for detection, surveillance and prognostication of bladder cancer (English)

1 reference

20 August 2017

J Alfred Witjes

1 reference

20 August 2017

Olaf P J Vrooman

1 reference

20 August 2017

publication date

1 March 2009

1 reference

International Journal of Urology

20 August 2017

published in

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

page(s)

234-243

1 reference

Urine markers for bladder cancer surveillance: a systematic review

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Molecular prognostication in bladder cancer--a current perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Applications of microarrays to histopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Tissue microarrays: what will they bring to molecular and anatomic pathology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Large-scale integration of cancer microarray data identifies a robust common cancer signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Comparative genomic hybridization (CGH) of augmentation cystoplasties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: A microarray validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Identifying distinct classes of bladder carcinoma using microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Proteome analysis: biological assay or data archive?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Mass spectrometry and protein analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Current achievements using ProteinChip Array technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Urinary biomarker profiling in transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

DNA-based molecular cytology for bladder cancer surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Use of polymerase chain reaction analysis of urinary DNA to detect bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Telomerase: its clinical relevance in the diagnosis of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Tumor markers in the diagnosis of primary bladder cancer. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

A side by side comparison of cytology and biomarkers for bladder cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

What determines differentiation of urothelial umbrella cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Survivin expression is associated with bladder cancer presence, stage, progression, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Tumor necrosis factor (TNF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Cachectin and tumour necrosis factor as two sides of the same biological coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Possible correlation between polymorphism in the tumor necrosis factor-beta gene and the clinicopathological features of bladder cancer in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Expression of the epidermal growth factor receptor family in normal and malignant urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Targeting EGFR in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Immunohistochemical markers in urinary bladder carcinomas from paraffin-embedded archival tissue after storage for 5-70 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Next-generation DNA sequencing methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Highly specific urine-based marker of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Relevance of Urine Telomerase in the Diagnosis of Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

Urine Telomerase Activity for the Detection of Bladder Cancer in Females

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2008.02225.X

10.1111/J.1442-2042.2008.02225.X

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference